Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F22%3AA2302JJV" target="_blank" >RIV/61988987:17110/22:A2302JJV - isvavai.cz</a>

Result on the web

<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000851364100020" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000851364100020</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/bloodadvances.2021006713" target="_blank" >10.1182/bloodadvances.2021006713</a>

Result language

angličtina

Original language name

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

Original language description

The IKEMA study (Randomized, Open Label, Multicenter Study Assessing the Clinical Benefit of Isatuximab CombinedWith Carfilzomib [Kyprolis((R))] and Dexamethasone Versus CarfilzomibWith Dexamethasone in PatientsWith Relapse and/or Refractory Multiple Myeloma Previously TreatedWith 1 to 3 Prior Lines; #NCT03275285) was a randomized, open-label, multicenter phase 3 study investigating isatuximab plus carfilzomib and dexamethasone (Isa-Kd) vs Kd in patients with relapsedmultiple myeloma. This subanalysis analyzed the depth of response of Isa-Kd vs Kd. The primary end point was progression-free survival (PFS); secondary end points included overall response rate, very good partial response or better (>= VGPR) rate, complete response (CR) rate, and minimal residual disease (MRD) negativity rate (assessed in patients with >= VGPR by next-generation sequencing at a 10(-5) sensitivity level). At amedian follow-up of 20.7 months, deeper responses were observed in the Isa-Kd arm vs the Kd arm, with >= VGPR 72.6% vs 56.1% and CR of 39.7% vs 27.6%, respectively. MRD negativity occurred in 53 (29.6%) of 179 patients in the Isa-Kd arm vs 16 (13.0%) of 123 patients in the Kd arm, with 20.1% (Isa-Kd, 36 of 179 patients) vs 10.6% (Kd, 13 of 123 patients) reachingMRD-negative CR status. Achieving MRD negativity resulted in better PFS in both arms. A positive PFS treatment effect was seen with Isa-Kd in both MRD-negative patients (hazard ratio, 0.578; 95% CI, 0.052-6.405) and MRD-positive patients (hazard ratio, 0.670; 95% CI, 0.452-0.993). Exploratory analysis indicates that both current CR andMRD-negative CR rates are underestimated due toM-protein interference (potential adjusted CR rate, 45.8%; potential adjustedMRD-negative CR rate, 24.0%). In conclusion, there was a clinically meaningful improvement in depth of response with Isa-Kd. The CR rate in Isa-Kd was 39.7%.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Blood Advances

ISSN

2473-9529

e-ISSN

—

Volume of the periodical

—

Issue of the periodical within the volume

15

Country of publishing house

US - UNITED STATES

Number of pages

10

Pages from-to

4506-4515

UT code for WoS article

000851364100020

EID of the result in the Scopus database

—